Search for dissertations about: "population pharmacokinetics"
Showing result 1 - 5 of 70 swedish dissertations containing the words population pharmacokinetics.
-
1. Piperaquine - Bioanalys, drug metabolism and pharmacokinetics
Abstract : Malaria is one of the most abundant parasitic diseases in the world affecting many of the poorest economies. The estimated prevalence is 300 to 700 million clinical episodes each year with up to 3 million deaths. READ MORE
-
2. Clinical pharmacokinetics and pharmacodynamics of antimalarial combination therapy
Abstract : In the face of growing drug resistance, the World Health Organization (WHO) has issued recommendations strongly encouraging the use of combination therapies to combat uncomplicated malaria. Amongst the most effective treatments are those combining an artemisinin derivative with a longer acting component such as amodiaquine, lumefantrine or piperaquine. READ MORE
-
3. New Approaches for Levodopa Treatment in Parkinson’s Disease
Abstract : Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in dopamine depletion. Levodopa is the most effective symptomatic treatment, however, disease progression along with the unfavorable pharmacokinetics of levodopa makes the disease increasingly difficult to treat with time. READ MORE
-
4. Pharmacokinetic drug-drug interactions in the management of malaria, HIV and tuberculosis
Abstract : Malaria, Human Immunodeficiency Virus (HIV) and tuberculosis (TB) are global health problems having their worst situation in sub-Saharan Africa. Consequently, concomitant use of antimalarial, antiretroviral and antitubercular drugs may be needed, resulting in a potential risk of drug-drug interactions. READ MORE
-
5. Pharmacometric Models to Improve Treatment of Tuberculosis
Abstract : Tuberculosis (TB) is the world’s most deadly infectious disease and causes enormous public health problems. The comorbidity with HIV and the rise of multidrug-resistant TB strains impede successful therapy through drug-drug interactions and the lack of efficient second-line treatments. READ MORE
